¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Cancer chemotherapy and biological response modifiers."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • conditioned response
    Á¶°Ç¹ÝÀÀ
  • consummatory response
    ¼ºÃë¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • chemotactic response
    È­ÇÐÁÖ¼º¹ÝÀÀ, È­Çнò¸²¹ÝÀÀ
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • evoked response
    À¯¹ß¹ÝÀÀ
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • frequency response curve
    Á֯ļö¹ÝÀÀ°î¼±
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • inverse response
    ¿ª¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • conditioned emotional response
    Á¶°Ç°¨Á¤¹ÝÀÀ
  • conditioned fear response
    Á¶°Ç°øÆ÷¹ÝÀÀ
  • consummatory response
    ¼ºÃë¹ÝÀÀ
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • frenquency response curve
    Á֯ļö¹ÝÀÀ°î¼±
  • response curve
    ¹ÝÀÀ°î¼±
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • delayed response
    Áö¿¬¹ÝÀÀ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • emotional response
    °¨Á¤¹ÝÀÀ
  • evoked response
    À¯¹ß¹ÝÀÀ
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • ulcer-cancer
    ±Ë¾ç¾Ï(±Ë¾ç¾Ï).
  • ulcer-cancer
    ±Ë¾ç¾Ï(Ï÷åËäß)
  • ureteral cancer
    ¿ä°ü¾ÏÁ¾
  • uterine cancer
    ÀڱþÏ(í­Ïà ).
  • vaginal cancer
    Áú¾Ï
  • water cancer =gangrenous stomatitis
    ¼ö¾Ï(â©äß) ±«»ç¼º±¸³»¿°(ÎÕÞÝàõÏ¢Ò®æú)
  • biologic test ; biological test
    »ý¹°ÇÐÀû ½ÃÇè(¡­ãËúÐ).
  • biological
    [¹Ì»ý,±â»ý,³»°ú,¿Ü°ú,°áÇÙ,ÀÓº´,¸é¿ª,°£È£,À¯Àü]»ý¹°ÇÐÀûÀÎ.
  • biological
    »ý¹°ÇÐÀûÀÎ
  • biological antagonism
    »ý¹°ÇÐÀû ±æÇ×(¡­±æÇ×).
  • biological antagonism
    »ý¹°ÇÐÀû ±æÇ×(¡­ÑÏù÷)
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
  • biological assay
    Àθí[¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ] »ý¹°ÇÐÀû ¾Æ¼¼ÀÌ(¡­ËþïÒ).
  • biological assay
    »ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ)
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
CHT chemotherapy; combined hormone therapy; contralateral head turning
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
IAC image analysis cytometry; ineffective airway clearance; internal auditory canal; interposed abdomina...
ISC immunoglobulin-secreting cells; insoluble collagen; International Society of Cardiology; Internation...
ITC imidazolyl-thioguanine chemotherapy; Interagency Testing Committee; in the canal [hearing aid]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
EORTC European Organisation for Research and Treatment of Cancer
EPIC European Prospective Investigation into Cancer and Nutrition
HNC Head and neck cancer
SCCHN squamous cell cancer of the head and neck
ACCESS Access to Community Care and Effective Services and Support
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • explosion and fire hazard
    Æø¹ß ÀÎÈ­¼º À§Çè
  • Food and Drug Administration
    ½ÄǰÀǾà±â±¸
  • H and D curve
    Ư¼º °î¼±
  • habit and impulse disorder
    ½À°ü ¹× Ãæµ¿ Àå¾Ö, ½À°ü ¹× Ãæµ¿º´
  • hand and foot disease
    ¼Õ¹ß º´, ¼öÁ· º´
  • hand foot and mouth disease
    ¼öÁ·±¸ º´, ¼Õ¹ßÀÔ º´, ¼Õ¹ß ¹× ±¸°­ Áúȯ, ¼Õ-¹ß-±¸°­ Áúȯ
    1. ÄÛ»çŰ ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ »ý±ä µå¹® Àå ¹ÙÀÌ·¯½º¼º °¨¿° Áúȯ. 2. °æÁõÀ̳ª ´ë´ÜÈ÷ °¨¿°·ÂÀÌ ÀÖ´Â ¼Ò¾ÆÀÇ ¹ÙÀÌ·¯½º º´À¸·Î¼­, ÀÔ, ¼öÁ·¿¡ ¼öÆ÷¼º º´º¯À» º¼ ¼ö ÀÖ´Â °ÍÀÌ ±× Ư¡ÀÌ´Ù. 3. ÄÛ»çŰ ¹ÙÀÌ·¯½º A16ÀÇ °¨¿°À¸·Î ¼Õ, ¹ß, ÇÏÁö, ÀÔ¼Ó¿¡ ÀÛÀº ¼öÆ÷°¡ »ý±â´Â Áúº´. ÁÖ·Î Á¥¸ÔÀÌ¿¡°Ô Àß ³ªÅ¸³ª´Â °¨¿°ÁõÀε¥, 6°³¿ù ¹Ì¸¸ÀÇ Á¥¸ÔÀÌ¿Í 4¼¼ ÀÌ»óÀÇ ¾î¸°ÀÌ¿¡°Ô´Â µå¹°°Ô °¨¿°µÈ´Ù. ³²ÀÚ ¾î¸°ÀÌ¿¡°Ô ¸¹°í ¼ºÀο¡°Ôµµ ³ªÅ¸³­´Ù. ¿©¸§Ã¶¿¡ ÁÖ·Î ¹ßº´Çϰí 4~6Àϰ£ÀÇ Àẹ±â¸¦ °ÅÄ£´Ù. Áõ¼¼´Â ´ëü·Î °¡º±´Ù. 1957³â ij³ª´Ù Åä·ÐÅä¿¡¼­ À¯ÇàÇßÀ» ¶§ ·Îºó½¼ µîÀÌ ÀÌ Áõ¼¼¿¡ ´ëÇØ ±â·ÏÇß°í, ´º¿åÁÖ ÄÛ»çŰ¿¡¼­ óÀ½À¸·Î ÀÌ ¹ÙÀÌ·¯½º¸¦ ºÐ¸®½ÃŲ µ¥¼­ ±× Áö¹æ¸íÀ» µû¼­ ¸í¸íÇÏ¿´´Ù. ±× ´ç½Ã º´¿øÃ¼´Â ÄÛ»çŰ A16 ¹ÙÀÌ·¯½º¿´À¸³ª, ÈÄ¿¡ ÄÛ»çŰ A5, A10°ú ¿£Å×·Î ¹ÙÀÌ·¯½º 71Çü¿¡ ÀÇÇØ¼­µµ °°Àº Áõ¼¼ÀÇ º´ÀÌ ³ªÅ¸³­´Ù´Â °ÍÀÌ ¹àÇôÁ³´Ù. ÁÖ·Î ºñ¸» °¨¿°, °æ±¸ °¨¿°À¸·Î Àü¿°µÈ´Ù.
  • Harris and Ray test
    Ç츮½º-·¹ÀÌ ½ÃÇè
    ¿äÁßÀÇ ºñŸ¹Î C¿¡ ´ëÇÑ ¹Ì·® ÀûÁ¤¹ý.
  • heat and cold therapy
    ³Ã¿Â ¿ä¹ý
    Â÷°¡¿î ÆÐµå¿Í ¶ß°Å¿î ÆÐµå¸¦ ¹ø°¥¾Æ°¡¸ç º´¼Ò¿¡ ´ë°í Ç÷¾× ¼øÈ¯À» ÃËÁø½Ã۰í ÅëÁõÀ» ¿ÏÈ­½ÃŰ´Â ¹æ¹ý.
  • heating and cooling temperature-place-time profile
    °¡¿­ ¹× ³Ã°¢ ¿Âµµ-À§Ä¡-½Ã°£ Çü
  • Hines and Brown test
    ÇÏÀνº ºê¶ó¿î ½ÃÇè
    ¾óÀ½ ¹°¿¡ ÇÑÂÊ ¼ÕÀ» ´ã±×°í Ç÷¾ÐÀÇ ¹ÝÀÀÀ» ÃøÁ¤ÇÑ´Ù °úµµ·Î Ç÷¾ÐÀÌ »ó½ÂÇϸé ÀáÀ缺 °íÇ÷¾Ð »óŸ¦ ¶æÇÑ´Ù.
  • incision and drainage
    Àý°³ ¹è³ó
    »óó, ±Ë¾ç, °øµ¿¿¡¼­ ¾×ü³ª ¹è¼³¹°À» ü°èÀûÀ¸·Î ¹èÃâ½ÃŰ´Â °Í.
  • infant and child
    ¿µÀ¯¾Æ, À¯¼Ò¾Æ
    ¿µ¾Æ±â·ÎºÎÅÍ »çÃá±â±îÁöÀÇ »ç¶÷.
  • inlay with pin and post
    À¯Á¤ Àη¹ÀÌ
    Àη¹ÀÌü¿¡ Æ÷½ºÆ® ¶Ç´Â ÇÉÀ» º´¿ëÇÏ¿© º¸Áö·ÂÀ» °­È­½ÃŲ °Í.
  • lateral and protrusive excursion
    Ãø¹æ ¹× Àü¹æ Á¢ÃË ¿îµ¿
  • lateral cord and associated anterior cornual syndrome
    Ãø»è µ¿Ãø Àü°¢ ÁõÈıº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
inflammatory response A part of innate immunity. Inflammation occurs when tissues are injured by viruses, bacteria, trauma, chemicals, heat, cold or any other harmful stimulus. Chemicals including bradykinin, histamine, serotonin and others are released by specialised cells. These chemicals attract tissue macrophages and white blood cells to localise in an area to engulf (phagocytize) and destroy foreign substances. A byproduct of this activity is the formation of pus--a combination of white blood cells, bacteria and foreign debris. The chemical mediators released during the inflammatory response give rise to the typical findings associated with inflammation.
(27 Sep 1997)
isomorphic response An isomorphic reaction seen in response to trauma in previously uninvolved sites of patients with skin diseases including psoriasis and lichen planus, typically with lesions in a linear pattern at sites of scratching or a scar.
Synonym: isomorphic response.
(05 Mar 2000)
oculomotor response Widespread myogenic potential evoked by visual stimuli.
(05 Mar 2000)
orienting response An aspect of attending in which an organism's initial response to a change or to a novel stimulus is such that the organism becomes more sensitive to the stimulation; e.g., dilation of the pupil of the eye in response to dim light.
Synonym: investigatory reflex, orienting response.
(05 Mar 2000)
overall response rate <pharmacology> Sum of complete and partial tumour responses seen in a study, divided by the number of evaluable patients.
(05 Jan 1998)
target response In conditioning, any behaviour or specific response chosen by the experimenter; its frequency is intended to increase or decrease by the judicious pairing with it of a reinforcer when it occurs.
Synonym: target behaviour, target response.
(05 Mar 2000)
th1 response <immunology> An acquired immune response whose most prominent feature is high cytotoxic T lymphocyte activity relative to the amount of antibody production. The Th1 response is promoted by CD4+ Th1 T-helper cells.
See: Th2 Response.
(09 Oct 1997)
th2 response <immunology> An acquired immune response whose most prominent feature is high antibody production relative to the amount of cytotoxic T lymphocyte activity The Th2 response is promoted by CD4+ Th2 T-helper cells.
See: TO Response.
(09 Oct 1997)
early-phase response Prompt onset of symptoms following an antigenic stimulus.
(05 Mar 2000)
triple response <immunology> The vascular changes in the skin in response to mild mechanical injury, an outward spreading zone of reddening flare) followed rapidly by a weal (swelling) at the site of injury.
Redness, heat and swelling, three of the cardinal signs of inflammation, are present.
(18 Nov 1997)
evoked response An alteration in the electrical activity of a region of the nervous system through which an incoming sensory stimulus is passing; may be somatosensory (SER), auditory (BAER), or visual (VER).
See: evoked potential.
(05 Mar 2000)
evoked response audiometry A type of electrophysiologic audiometry in which electrical potentials of neural impulses from the cochlear nerve and various levels in the brain in response to acoustic stimulation are used to localise the site of a lesion causing a hearing loss.
(05 Mar 2000)
unconditioned response A response, such as salivation, which is a part of the animal or human repertoire.
Compare: conditioned response.
(05 Mar 2000)
flight or fight response See: emergency theory.
(05 Mar 2000)
late-phase response Recurrence of symptoms after an appreciable interval following challenge with an antigen; preceded by an initial early-phase response.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • mild and bitter
    ´Ü¸À ¾´¸ÀÀÌ ¹Ý¹ÝÀÎ ¸ÆÁÖ
  • milk and water
    ±èºüÁø;¸ß¾ø´Â;¸÷½Ã °¨»óÀûÀÎ
  • mix and match
    ±ÕÇüÀÌ ¸ÂÁö ¾Ê´Â °Í ³¢¸®ÀÇ Â¦Áö¿ò
  • nuts and bolts
    (±â°èÀÇ)ÀÛµ¿ºÎ(ºÐ);¿îÀü;°æ¿µ;(»ç¹°ÀÇ)±âº» ¿äÁ¡
  • park-and-ride
    Â÷·Î ¿ª±îÁö °¡¼­ ÁÖÂ÷Çϰí ÀüÂ÷³ª ¹ö½º·Î °¥¾ÆÅ¸´Â (¹æ½Ä)
  • quick and dirty
    (Ä«¿îÅͽÄÀÇ)°£ÀÌ ½Ä´ç(snack bar)
  • rag-and-none man
    ³Õ¸¶ÁÖÀÌ
  • rank-and-file
    Æò»ç¿øÀÇ;(ÁöµµÀÚ°¡ ¾Æ´Ñ)ÀÏ¹Ý Á¶ÇÕ¿øÀÇ;¼­¹Î.ÀÏ¹Ý ´ëÁßÀÇ;(Àå±³°¡ ¾Æ´Ñ)»çº´ÀÇ
  • rank-and-filer
    »çº´;ÀϹݽùÎ;¼­¹Î;Æò»ç¿øµé;Æò´ç¿øµé
  • reach and frequency
    µµ´Þµµ¿Í µµ´Þ Ƚ¼ö(ÀÏ·ÃÀÇ ±¤°í Ȱµ¿À¸·Î ±× °­°í°¡ ¾î´À Á¤µµ ħÅõ Çߴ°¡¸¦ ÃøÁ¤ÇÒ ¶§ »ç¿ëµÇ´Â µÎ°¡Áö ¿ä¼Ò)
  • reaper and binder
    ¹ÙÀδõ(º£¾î¼­ ´Ù¹ßÀ» ¹­´Â ±â°è)
  • research and development
    ¿¬±¸¿Í °³¹ß
  • rest and recuperation
    (º´»çÀÇ)ÈÞ°¡¿Í ÈÞ¾ç
  • rhythm and blues
    ¸®µë ¾Øµå ºí·ç½º(ÈæÀÎ À½¾ÇÀÇ ÀÏÁ¾,rock'n'rollÀÇ ¸ðü)
  • right of visit (and search)
    =RIGHT OF SEARCH
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á